Skip to content

Nasdaq · CIK 0001516551

SKYE Skye Bioscience, Inc.

Insider trading from SEC Form 4. Last filing 18 d ago. Close $1.69 on Oct 9, 2026, +8% from the 52-week low and -88% from the high.

Last 90 days

Net insider value
-$609k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$609k by 2 insiders
Insiders on file
10
with a Form 4 at this company

Price and insider trades, last year

SKYEOct 9, 2026 · close 1.69

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Skye Bioscience, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
53Moderate5AM Partners VII, LLC
owner
sell
$240k
148,079 shares
-104%+9% from low-96% from high
56ModerateAndrew J. Schwab
director, owner
sell
$240k
148,079 shares
-104%+9% from low-96% from high
33Weak5AM Partners VII, LLC
owner
sell
$65k
33,892 shares
-19%+1% from low-96% from high
36WeakAndrew J. Schwab
director, owner
sell
$65k
33,892 shares
-19%+1% from low-96% from high
47Moderate5AM Partners VII, LLC
owner
sell
$801k
231,405 shares
-14%+196% from low-44% from high
50ModerateAndrew J. Schwab
director, owner
sell
$801k
231,405 shares
-14%+196% from low-44% from high
45ModerateTuan Tu Diep
Chief Development Officer
sell
$98k
19,574 shares
-19%-
54ModerateKaitlyn Arsenault
Chief Financial Officer
sell
$217k
43,396 shares
-21%-
61NotablePunit Dhillon
Chief Executive Officer
sell
$414k
82,910 shares
-20%-
52ModeratePaul A. Grayson
director
sell
$432k
86,551 shares
-25%-

Transactions

The last 45 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 22, 20265AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-27,612$1.65$46k114,85118 d ago
Sep 22, 2026Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-27,612$1.65$46k114,85118 d ago
Sep 22, 20265AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-1,088$1.65$1,7954,52818 d ago
Sep 22, 2026Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-1,088$1.65$1,7954,52818 d ago
Sep 23, 2026Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-114,851$1.61$185k018 d ago
Sep 23, 20265AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-114,851$1.61$185k018 d ago
Sep 23, 20265AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-4,528$1.61$7,290018 d ago
Sep 23, 2026Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-4,528$1.61$7,290018 d ago
Sep 16, 20265AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-32,607$1.91$62k142,46324 d ago
Sep 16, 2026Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-32,607$1.91$62k142,46324 d ago
Sep 16, 20265AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-1,285$1.91$2,4545,61624 d ago
Sep 16, 2026Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-1,285$1.91$2,4545,61624 d ago
Feb 6, 2026Puneet S. Arora
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+125,000$0.00$0125,000Feb 9, 2026
Feb 6, 2026Kaitlyn Arsenault
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+125,000$0.00$0125,000Feb 9, 2026
Aug 21, 20255AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-58,642$3.57$209k1,621,043Aug 22, 2025
Aug 21, 2025Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-58,642$3.57$209k1,621,043Aug 22, 2025
Aug 21, 20255AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-2,314$3.57$8,26163,963Aug 22, 2025
Aug 21, 2025Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-2,314$3.57$8,26163,963Aug 22, 2025
Aug 22, 20255AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-163,979$3.42$561k1,457,064Aug 22, 2025
Aug 22, 2025Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Ventures II, L.P.
-163,979$3.42$561k1,457,064Aug 22, 2025
Aug 22, 20255AM Partners VII, LLC
owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-6,470$3.42$22k57,493Aug 22, 2025
Aug 22, 2025Andrew J. Schwab
director, owner
SOpen-market sale
Common Stockindirect: By 5AM Co-Investors II, L.P.
-6,470$3.42$22k57,493Aug 22, 2025
Feb 24, 2025Kaitlyn Arsenault
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+150,000$0.00$0150,000Feb 26, 2025
Feb 24, 2025Annalisa Jenkins
director
AGrant or award
Stock Option (Right to Buy)derivative
+35,000$0.00$035,000Feb 26, 2025
Feb 24, 2025Paul A. Grayson
director
AGrant or award
Stock Option (Right to Buy)derivative
+135,000$0.00$0135,000Feb 26, 2025
Feb 24, 2025Tuan Tu Diep
Chief Development Officer
AGrant or award
Stock Option (Right to Buy)derivative
+150,000$0.00$0150,000Feb 26, 2025
Feb 24, 2025Deborah H. Charych
director
AGrant or award
Stock Option (Right to Buy)derivative
+35,000$0.00$035,000Feb 26, 2025
Feb 24, 2025Puneet S. Arora
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+38,000$0.00$038,000Feb 26, 2025
Feb 24, 2025Punit Dhillon
Chief Executive Officer
AGrant or award
Stock Option (Right to Buy)derivative
+250,000$0.00$0250,000Feb 26, 2025
Nov 15, 2024Tuan Tu Diep
Chief Development Officer
SOpen-market sale
Common Stock
-85$5.55$472101,748Nov 20, 2024
Nov 18, 2024Tuan Tu Diep
Chief Development Officer
SOpen-market sale
Common Stock
-19,489$4.99$97k82,259Nov 20, 2024
Nov 15, 2024Kaitlyn Arsenault
Chief Financial Officer
SOpen-market sale
Common Stock
-190$5.55$1,055209,548Nov 19, 2024
Nov 15, 2024Punit Dhillon
Chief Executive Officer
SOpen-market sale
Common Stock
-364$5.55$2,020412,369Nov 19, 2024
Nov 15, 2024Paul A. Grayson
director
SOpen-market sale
Common Stock
-307$5.55$1,704345,945Nov 19, 2024
Nov 18, 2024Punit Dhillon
Chief Executive Officer
SOpen-market sale
Common Stock
-82,546$4.99$412k329,823Nov 19, 2024
Nov 18, 2024Paul A. Grayson
director
SOpen-market sale
Common Stock
-86,244$4.99$430k259,701Nov 19, 2024
Nov 18, 2024Kaitlyn Arsenault
Chief Financial Officer
SOpen-market sale
Common Stock
-43,206$4.99$216k166,342Nov 19, 2024
Oct 28, 2024Kaitlyn Arsenault
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+125,000$0.00$0125,000Oct 30, 2024
Oct 28, 2024Deborah H. Charych
director
AGrant or award
Stock Option (Right to Buy)derivative
+70,000$0.00$070,000Oct 30, 2024
Oct 28, 2024Punit Dhillon
Chief Executive Officer
AGrant or award
Stock Option (Right to Buy)derivative
+650,000$0.00$0650,000Oct 30, 2024
Oct 28, 2024Tuan Tu Diep
Chief Development Officer
AGrant or award
Stock Option (Right to Buy)derivative
+125,000$0.00$0125,000Oct 30, 2024
Oct 28, 2024Paul A. Grayson
director
AGrant or award
Stock Option (Right to Buy)derivative
+70,000$0.00$070,000Oct 30, 2024
Oct 28, 2024Annalisa Jenkins
director
AGrant or award
Stock Option (Right to Buy)derivative
+70,000$0.00$070,000Oct 30, 2024
Oct 28, 2024Andrew J. Schwab
director
AGrant or award
Stock Option (Right to Buy)derivative
+70,000$0.00$070,000Oct 30, 2024
Oct 28, 2024Karen L. Smith
director
AGrant or award
Stock Option (Right to Buy)derivative
+70,000$0.00$070,000Oct 30, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SKYE insider trading: Skye Bioscience, Inc. | InsiderTell